Abstract

The origin of SARS-CoV-2 variants of concern remains unclear. Here, we test whether intra-host virus evolution during persistent infections could be a contributing factor by characterizing the long-term SARS-CoV-2 infection dynamics in an immunosuppressed kidney transplant recipient. Applying RT-qPCR and next-generation sequencing (NGS) of sequential respiratory specimens, we identify several mutations in the viral genome late in infection. We demonstrate that a late viral isolate exhibiting genome mutations similar to those found in variants of concern first identified in UK, South Africa, and Brazil, can escape neutralization by COVID-19 antisera. Moreover, infection of susceptible mice with this patient’s escape variant elicits protective immunity against re-infection with either the parental virus and the escape variant, as well as high neutralization titers against the alpha and beta SARS-CoV-2 variants, B.1.1.7 and B.1.351, demonstrating a considerable immune control against such variants of concern. Upon lowering immunosuppressive treatment, the patient generated spike-specific neutralizing antibodies and resolved the infection. Our results suggest that immunocompromised patients could be a source for the emergence of potentially harmful SARS-CoV-2 variants.

Here, in a longitudinal case study, Weigang et al. demonstrate that evolution of SARS-CoV-2 within a persistently infected immunosuppressed patient can result in the emergence of novel variants with reduced sensitivity to antibody neutralization.

Details

Title
Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants
Author
Weigang Sebastian 1   VIAFID ORCID Logo  ; Fuchs, Jonas 1   VIAFID ORCID Logo  ; Zimmer, Gert 2   VIAFID ORCID Logo  ; Schnepf, Daniel 1   VIAFID ORCID Logo  ; Kern, Lisa 1 ; Beer, Julius 1 ; Luxenburger Hendrik 3   VIAFID ORCID Logo  ; Ankerhold Jakob 1 ; Falcone Valeria 1   VIAFID ORCID Logo  ; Kemming Janine 3 ; Hofmann, Maike 3   VIAFID ORCID Logo  ; Thimme, Robert 3   VIAFID ORCID Logo  ; Neumann-Haefelin Christoph 3   VIAFID ORCID Logo  ; Ulferts Svenja 4   VIAFID ORCID Logo  ; Grosse, Robert 4   VIAFID ORCID Logo  ; Hornuss, Daniel 5   VIAFID ORCID Logo  ; Tanriver Yakup 6 ; Rieg Siegbert 5 ; Wagner, Dirk 5 ; Huzly Daniela 1 ; Schwemmle, Martin 1   VIAFID ORCID Logo  ; Panning Marcus 1   VIAFID ORCID Logo  ; Kochs Georg 1   VIAFID ORCID Logo 

 University of Freiburg, Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9) 
 Institute of Virology and Immunology, Bern & Mittelhäusern, Switzerland, and Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157) 
 University of Freiburg, Department of Medicine II, Freiburg University Medical Center, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9) 
 Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Institute of Experimental and Clinical Pharmacology and Toxicology, Freiburg, Germany (GRID:grid.5963.9) 
 University of Freiburg, Division of Infectious Diseases, Dept. Med. II, Freiburg University Medical Center, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9) 
 University of Freiburg, Division of Nephrology, Dept. Med. IV, Freiburg University Medical Center, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2593361300
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.